Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Burning Rock Biotech (BNR) Non-Current Deffered Revenue (2019 - 2020)

Burning Rock Biotech has reported Non-Current Deffered Revenue over the past 2 years, most recently at $39684.9 for Q4 2020.

For Q4 2020, Non-Current Deffered Revenue fell 71.78% year-over-year to $39684.9; the TTM value through Dec 2020 reached $39684.9, down 71.78%, while the annual FY2020 figure was $40000.0, 72.13% down from the prior year.
Non-Current Deffered Revenue for Q4 2020 was $39684.9 at Burning Rock Biotech, up from $39000.0 in the prior quarter.
Over five years, Non-Current Deffered Revenue peaked at $140603.8 in Q4 2019 and troughed at $37000.0 in Q2 2020.